The Dana Farber Consortium Protocol for the Treatment of Adolescents and Young Adults With Acute Lymphoblastic Leukemia: A Single Institution Experience in Saudi Arabia

In this retrospective study we sought to evaluate the feasibility of using the Dana Farber Consortium Protocol in Saudi adolescents and young adult patients with acute lymphoblastic leukemia. The 3-year leukemia-free survival and overall survival rates were 70.2% and 72.5%, respectively. Toxicities included infection, mortality during induction, and pancreatitis, but the incidence and severity of osteonecrosis were less than in Western populations, and no venous thromboembolism was found with the use of enoxaparin prophylaxis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research